HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Build Back Better' Has $150M For FDA IT Upgrade

Executive Summary

Agency would get $300m, half going to modernizing its IT systems. It recently ran into disagreement with industry after using user fees to pay for some upgrades.

You may also be interested in...



MDUFA V: Industry, FDA Tangle Over TAP Program, Agency Finances, Reinstatement Of Fifth-Year Offset Funds

In newly published meeting minutes, industry and the US FDA continued to clash over a proposal to create a new pre-submission advisory program and what to do with carryover user-fee funds.

FDA’s Woodcock Pitches Large IT Modernization Plan

In a new blogpost the US FDA acting commissioner says millions of extra dollars in President Joe Biden’s recently proposed budget would help integrate the agency’s IT systems and improve efficiencies.

Exit Interview: Abernethy Tells Why She’s Leaving FDA – But Staying On Her Own Path

The FDA’s outgoing second-in-command, Amy Abernethy, is confident she’s leaving the agency in good hands but plans to continue to advocate for patients by focusing on areas such as trial design and use of real-world evidence. In this interview with Medtech Insight, Abernethy also talks about the work she put in to make sure there was a change in IT culture at the agency, among other topics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel